

A NEW IN VIVO METABOLITE OF VITAMIN D₃ :
1,25,26-TRIHIDROXYVITAMIN D₃

T. A. Reinhardt*, J. L. Napoli, D. C. Beitz, E. T. Littledike,
and R. L. Horst

National Animal Disease Center, Agricultural Research, Science and
Education Administration, U. S. Department of Agriculture, P.O. Box 70,
Ames, IA 50010; Department of Biochemistry, The University of Texas
Health Science Center, Dallas, TX 75235; and Department of Animal
Science, Iowa State University, Ames, IA 50011

Received January 26, 1981

SUMMARY

A new metabolite of vitamin D₃ was detected with a modified receptor-binding assay in plasma of cows given large parenteral doses of vitamin D₃. This metabolite has been identified as 1,25,26-trihydroxyvitamin D₃ by comigration of the *in vivo*-isolated metabolite with synthetic 1,25(S),26-trihydroxyvitamin D₃ on two different high-pressure liquid chromatography systems and by mass spectroscopy.

INTRODUCTION

Metabolism of vitamin D₃ to more polar and active metabolites has been well documented (1). Several new metabolites of vitamin D₃ have recently been described in detail (1-4); however, it has been pointed out that

* Address all correspondence to Dr. Timothy A. Reinhardt, National Animal Disease Center, AR-SEA, USDA, P.O. Box 70, Ames, IA 50010.

This investigation was supported in part by a NIH National Research Service Award AM06382 (TAR) from the NIAMD, by a NIH Grant AM26535 (JLN), by the Robert A. Welch Foundation Grant I-769 (JLN), and by a shared instrumentation grant GM27506 (UTHSCD). Journal paper No. J-10158 of the Iowa Agriculture and Home Economics Experiment Station, Ames, IA. Project No. 2393.

Disclaimer Statement

Mention of a trade name, proprietary product, or vendor does not constitute a guarantee or warranty by the U. S. Department of Agriculture or cooperating agencies and does not imply its approval to the exclusion of other products or vendors that may be suitable.

Abbreviations used: 1,25-(OH)₂D₃, 1,25-dihydroxyvitamin D₃; 1,24(R),25-(OH)₂D₃, 1,24(R),25-trihydroxyvitamin D₃; 1,25,26-(OH)₃D₃, 1,25,26-trihydroxyvitamin D₃; HPLC, high-pressure liquid chromatography.

several metabolites remain to be identified and chemically characterized (1).

During the development of a receptor assay for 1,24,25-trihydroxy-vitamin D₃ [1,24,25-(OH)₃D₃] in plasma, we found an unidentified vitamin D₃ metabolite that was more polar than 1,25-(OH)₂D₃ or 1,24,25-(OH)₃D₃ in plasma of cows receiving large parenteral doses of vitamin D₃. The compound was isolated in pure form, and we report here the structure of this new polar vitamin D₃ metabolite to be 1,25,26-(OH)₃D₃.

MATERIALS AND METHODS

Animals -- Jersey cows were treated as described (5), and blood was collected after 4 weeks of treatment. Blood obtained from untreated cows served as controls.

Apparatus -- High-pressure liquid chromatography (HPLC) was performed on a Model LC-204 HPLC (Waters Associates, Milford, MA). Mass spectra were obtained using a solid probe at 54 eV with a Finnigan Model 4021 spectrometer at 150°C above ambient.

Sterols -- Synthetic 1,25-(OH)₂D₃, 1,24(R),25-(OH)₃D₃, and 1,25(S),26-(OH)₃D₃ were provided by Dr. M. Uskokovic of Hoffman-LaRoche (Nutley, NJ). 1,25-Dihydroxy[³H-26,27]vitamin D₃ (160 Ci/mmol) was purchased from New England Nuclear (Boston, MA). 25,26-Dihydroxy-[³H-23,24]vitamin D₃ was prepared as previously described (6). 1,25,26-Trihydroxy[³H-23,24]vitamin D₃ was biosynthesized *in vitro* from 25,26-dihydroxy[³H-23,24]vitamin D₃ using a procedure described for the 1 α -hydroxylation of 25-hydroxyvitamin D₃ (7).

Receptor-binding assay -- The assay was performed as previously described (7), using chick intestinal cytosol and 1,25-(OH)₂[³H-26,27]-vitamin D₃ with the following modifications. The cytosol was prepared in a buffer consisting of 50 mM Tris-HCl, 300 mM KCl, 1.5 mM EDTA, 5 mM dithiothreitol and glycerol 10% (v/v), pH 7.5. Changes in this buffer's KCl concentration are noted in succeeding steps. The 1,25-(OH)₂D₃ receptor was precipitated from crude cytosol with 40% (NH₄)₂SO₄. The pellet obtained after centrifugation (16,000 x g) was dissolved in the buffer described (25 mM KCl) and chromatographed on a 2 x 5 cm column of Blue Sepharose CL-6B (Pharmacia Fine Chemicals, Piscataway, NJ). The column containing the 1,25-(OH)₂D₃ receptor was washed with 100 ml of the 25 mM KCl buffer. The 1,25-(OH)₂D₃ receptor was then eluted with 50 ml of buffer (0.6 M KCl). This receptor fraction was used in the assay.

Preparation of plasma for assay -- Plasma (5-10 ml) from normal and vitamin D₃-treated cows was extracted as described (8). This extract was chromatographed on a 0.6 x 15 cm Sephadex LH-20 column developed in hexane:chloroform:methanol (9:1:1). The initial 18 ml of column solvent were discarded, and the solvent was changed to hexane:chloroform:methanol (8:2:2). The next 10 ml were collected, dried under N₂, and subjected to

HPLC on a Zorbax Sil column 0.46 x 25 cm using hexane:isopropanol (83:17) at a flow rate of 2 ml/min. One-min (2 ml) fractions were collected, dried, and assayed using the receptor assay. Regions of binding were located, and a duplicate plasma extract was purified using the Zorbax Sil column above. The individual peak areas were isolated and rechromatographed on a 0.46 x 25 cm Zorbax ODS column developed in methanol:H₂O (80:20). Fractions (2 ml) again were collected and assayed for binding. This was done to confirm the homogeneity of the isolated compounds and their comigration with authentic standards.

Isolation of new vitamin D₃ metabolite -- Plasma (16 l) from vitamin D₃-treated cows was extracted (9), dried under vacuum, labeled with 1,25,26-(OH)₃[³H-23,24]vitamin D₃ (200,000 cpm), and chromatographed on a 4.0 x 60 cm Sephadex LH-20 column with 1.5 l of chloroform:hexane:methanol (50:48:2). The column contents were removed and extracted 2 times with methanol. The extract was dried under vacuum and rechromatographed on a 1.8 x 25 cm Sephadex LH-20 column in chloroform:hexane:methanol (75:23:2). The region corresponding to the elution of the 1,25,26-(OH)₃[³H-23,24]vitamin D₃ was collected (260-380 ml) and chromatographed by HPLC on a 0.46 x 25 cm Zorbax ODS column using methanol:H₂O (80:20). The 1,25,26-(OH)₃D₃ region (24-30 ml) was rechromatographed on a 0.46 x 25 cm Zorbax Sil column using methylene chloride:isopropanol (93:7), and the 1,25,26-(OH)₃D₃ region (22-26 ml) from this column was chromatographed on a 0.46 x 25 cm Zorbax Sil column in hexane:isopropanol (83:17). The sole 254 nm absorbing peak was recycled twice to confirm homogeneity and then collected for structural analysis. Five hundred ng of the pure compound were isolated.

RESULTS AND DISCUSSION

The HPLC receptor binding profiles of the purified plasma extracts from vitamin D₃-treated cows showed three distinct peaks of binding activity (Fig. 1). The new metabolite observed comigrated with synthetic 1,25(S),26-(OH)₃D₃ (Fig. 1). The two additional peaks comigrated with synthetic 1,25-(OH)₂D₃ and 1,24(R),25-(OH)₃D₃. The absence of the new metabolite in plasma extracts from control cows precluded further study of the controls (Fig. 1).

When the 1,25,26-(OH)₃D₃ isolate from the Zorbax Sil column (Fig. 1) was rechromatographed on a reverse-phase Zorbax ODS column and fractions were analyzed, the binding activity was found to be homogeneous and comigrate with synthetic 1,25(S),26-(OH)₃D₃ (Fig. 2). Both the 1,25-(OH)₂D₃ and 1,24,25-(OH)₃D₃ isolates from the Zorbax Sil column (Fig. 1) were found to be homogeneous and to comigrate with their




Figure 1. HPLC receptor binding profile of plasma extracts from normal and vitamin D₃-treated cows after purification on Sephadex LH-20. The profile represents elution from a Zorbax Sil column developed in hexane:isopropanol (83:17). Arrows indicate the elution positions of authentic standards.

respective synthetic standards on the Zorbax ODS column (data not shown). The comigration of the receptor binding activities with synthetic 1,25(S),26-(OH)₃D₃ on HPLC columns with different selectivities suggested that this new vitamin D₃ metabolite was 1,25,26-(OH)₃D₃.

Five hundred ng of this new metabolite of vitamin D₃ were isolated from 16 l of plasma from vitamin D₃-treated cows and subjected in part to mass spectrometric analysis. The mass spectrum of this new metabolite is characteristic of a trihydroxylated vitamin D₃ metabolite (Fig. 3). The molecular ion at m/e 432 and the three sequential losses of H₂O at m/e 414, 396, and 378 indicate the presence of 3 hydroxyl groups in addition to the 3 β -hydroxyl group. The peak at m/e 269 arises from side-chain cleavage and loss of H₂O from the remaining fragment. Loss of a second H₂O molecule provides the peak at m/e 251. The peak at m/e 152 arises from formal cleavage between carbons 7 and 8 to give rise to the A ring, plus carbons 6 and 7 fragment, containing 2 hydroxyl groups. Loss of H₂O from m/e 152 provides the base peak at m/e 134. The fragments at m/e 152 and 134 illustrate that the secosteroid nucleus of the vitamin has remained unchanged.




Figure 2. HPLC receptor binding profile of the 1,25,26-(OH)₃D₃ isolate, after purification on the Zorbax Sil column (Fig. 1), and re-chromatographed on a Zorbax ODS column developed in methanol:H₂O (80:20). Arrows indicate the elution positions of authentic standards.

A recent study (10) has concluded that kidney 1 α -hydroxylation probably is required for the expression of biological activity of 25,26-(OH)₂D₃ in vitamin D-deficient rats. To date, no such metabolite of vitamin D₃ has been isolated or identified. In the present communication, we have isolated and identified 1,25,26-(OH)₃D₃ from the plasma of vitamin D₃-treated cows. The cochromatography of this new *in vivo* metabolite of vitamin D₃ with synthetic 1,25(S),26-(OH)₃D₃ on HPLC




Figure 3. Mass spectrum of 1,25,26-(OH)₃D₃ isolated from vitamin D₃-treated cows.

systems with different selectivities and the mass spectrometric data strongly suggest that this newly discovered metabolite of vitamin D₃ is 1,25,26-(OH)₃D₃.

It may be significant that 1,25,26-(OH)₃D₃ has been detected and isolated only from cows treated with large doses of vitamin D₃ because cows are the only animals that have been shown to increase the production of 1,25-(OH)₂D₃ following the administration of large doses of vitamin D₃ (5, 11). This suggests that the 1,25,26-(OH)₃D₃ found may reflect the degradation of abnormally elevated levels of 1,25-(OH)₂D₃ in these cows.

Further structural and biological investigations are in progress in our laboratory.

ACKNOWLEDGMENT

We are grateful for the expertise of Bikash Pramanik in obtaining the mass spectra.

REFERENCES

1. Norman, A. W. (1979) Vitamin D: The Calcium Homeostatic Steroid Hormone, pp. 134-191, Academic Press, New York.
2. Horst, R. L. (1979) Biochem. Biophys. Res. Commun. 89, 286-293.
3. Wichmann, J. K., DeLuca, H. F., Schnoes, H. K., Horst, R. L., Shepard, R. M., and Jorgensen, N. A. (1979) Biochemistry 18, 4775-4780.
4. Ohnuma, N., Bannai, K., Yamaguchi, H., Hashimoto, Y., and Norman, A. N. (1980) Arch. Biochem. Biophys. 204, 387-391.
5. Horst, R. L. and Littledike, E. T. (1979) Vitamin D, Basic Research and Its Clinical Application, pp. 999-1001, Walter deGruyter & Co., New York.
6. Tanaka, Y., Shepard, R. A., DeLuca, H. F., and Schnoes, H. K. (1978) Biochem. Biophys. Res. Commun. 83, 7-13.
7. Tanaka, Y., Lorene, R. S., and DeLuca, H. F. (1975) Arch. Biochem. Biophys. 171, 521-526.
8. Horst, R. L., Shepard, R. M., Jorgensen, N. A., and DeLuca, H. F. (1979) Arch. Biochem. Biophys. 191, 512-523.
9. Bligh, E. G. and Dyer, W. J. (1959) Can. J. Biochem. Physiol. 37, 911-925.
10. Thomasset, M., Redel, J., Marche, P., Laborde, K., and Cuisinier-Gleizes, P. (1978) Steroids 32, 577-587.
11. Reinhardt, T. A. and Conrad, H. R. (1980) J. Nutr. 110, 1589-1596.